• ISSN 1674-8301
  • CN 32-1810/R
Volume 35 Issue 3
May  2021
Turn off MathJax
Article Contents
Ying Yang, Xiang Chen, Changyan Ma. Insulin receptor is implicated in triple-negative breast cancer by decreasing cell mobility[J]. The Journal of Biomedical Research, 2021, 35(3): 189-196. doi: 10.7555/JBR.34.20200082
Citation: Ying Yang, Xiang Chen, Changyan Ma. Insulin receptor is implicated in triple-negative breast cancer by decreasing cell mobility[J]. The Journal of Biomedical Research, 2021, 35(3): 189-196. doi: 10.7555/JBR.34.20200082

Insulin receptor is implicated in triple-negative breast cancer by decreasing cell mobility

doi: 10.7555/JBR.34.20200082
More Information
  • Corresponding author: Xiang Chen, Department of General Surgery, the Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu 214200, China. Tel: +86-510-87921210, E-mail: staff984@yxph.com; Changyan Ma, Department of Medical Genetics, School of Basic Medical Sciences, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu 211166, China. Tel: +86-25-86869463, E-mail: cyma@njmu.edu.cn
  • Received: 2020-06-03
  • Revised: 2020-06-18
  • Accepted: 2020-06-19
  • Published: 2020-08-28
  • Issue Date: 2021-05-28
  • Triple-negative breast cancer (TNBC) has a poor prognosis and typically earlier onset of metastasis in comparison with other breast cancer subtypes. It has been reported that insulin receptor (INSR) is downregulated in TNBC, however, its clinical significance and functions in TNBC remain to be elucidated. In this study, we found that INSR expression was significantly downregulated in TNBC, and overexpression of INSR suppressed cell migration and invasion in TNBC. In addition, the survival rate of breast cancer patients with low INSR expression was lower than that of patients with high INSR expression. INSR expression was significantly correlated with lymph node metastasis, clinical tumor stages, ER status, PR status, and the proliferation index Ki-67 expression. In summary, our study suggests that INSR may serve as a biomarker for breast cancer prognosis and it may be a potential target for TNBC treatment.

     

  • loading
  • [1]
    Dawood S. Triple-negative breast cancer: epidemiology and management options[J]. Drugs, 2010, 70(17): 2247–2258. doi: 10.2165/11538150-000000000-00000
    [2]
    Lee A, Djamgoz MBA. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies[J]. Cancer Treat Rev, 2018, 62: 110–122. doi: 10.1016/j.ctrv.2017.11.003
    [3]
    Periyasamy K, Sivabalan V, Baskaran K, et al. Cellular metabolic energy modulation by tangeretin in 7,12-dimethylbenz(a) anthracene-induced breast cancer[J]. J Biomed Res, 2016, 30(2): 134–141. doi: 10.7555/JBR.30.20150060
    [4]
    Chen F, Li Y, Qin N, et al. RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer[J]. J Biomed Res, 2020, 34(2): 129–138. doi: 10.7555/JBR.34.20190111
    [5]
    Kim C, Gao R, Sei E, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing[J]. Cell, 2018, 173(4): 879–893.e13. doi: 10.1016/j.cell.2018.03.041
    [6]
    Al-Mahmood S, Sapiezynski J, Garbuzenko OB, et al. Metastatic and triple-negative breast cancer: challenges and treatment options[J]. Drug Deliv Transl Res, 2018, 8(5): 1483–1507. doi: 10.1007/s13346-018-0551-3
    [7]
    Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism[J]. Nature, 2001, 414(6865): 799–806. doi: 10.1038/414799a
    [8]
    Adamo M, Raizada MK, LeRoith D. Insulin and insulin-like growth factor receptors in the nervous system[J]. Mol Neurobiol, 1989, 3(1-2): 71–100. doi: 10.1007/BF02935589
    [9]
    Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases[J]. Arch Physiol Biochem, 2008, 114(1): 23–37. doi: 10.1080/13813450801969715
    [10]
    Kalla Singh S, Brito C, Tan QW, et al. Differential expression and signaling activation of insulin receptor isoforms A and B: a link between breast cancer and diabetes[J]. Growth Factors, 2011, 29(6): 278–289. doi: 10.3109/08977194.2011.616200
    [11]
    Chen X, Wu J, Huang H, et al. Comparative profiling of triple-negative breast carcinomas tissue glycoproteome by sequential purification of glycoproteins and stable isotope labeling[J]. Cell Physiol Biochem, 2016, 38(1): 110–121. doi: 10.1159/000438613
    [12]
    Xue YB, Meehan B, Fu Z, et al. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer[J]. Nat Commun, 2019, 10(1): 557. doi: 10.1038/s41467-019-08380-1
    [13]
    Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8): 649–658. doi: 10.1016/j.neo.2017.05.002
    [14]
    Györffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients[J]. Breast Cancer Res Treat, 2010, 123(3): 725–731. doi: 10.1007/s10549-009-0674-9
    [15]
    Cortés J, André F, Gonçalves A, et al. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer[J]. Future Oncol, 2019, 15(17): 1951–1961. doi: 10.2217/fon-2019-0059
    [16]
    Lyons TG, Traina TA. Emerging novel therapeutics in triple-negative breast cancer[M]//Ahmad A. Breast Cancer Metastasis and Drug Resistance: Challenges and Progress. Cham: Springer, 2019: 377–399.
    [17]
    Wang SY, Beeghly-Fadiel A, Cai QY, et al. Gene expression in triple-negative breast cancer in relation to survival[J]. Breast Cancer Res Treat, 2018, 171(1): 199–207. doi: 10.1007/s10549-018-4816-9
    [18]
    Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428–440.e5. doi: 10.1016/j.ccell.2019.02.001
    [19]
    Saravia CH, Flores C, Schwarz LJ, et al. Patterns of mutation enrichment in metastatic triple-negative breast cancer[J]. Clin Med Insights Oncol, 2019, 13: 1179554919868482.
    [20]
    Khaled N, Bidet Y. New insights into the implication of epigenetic alterations in the EMT of triple negative breast cancer[J]. Cancers, 2019, 11(4): 559. doi: 10.3390/cancers11040559
    [21]
    Yu J, Zayas J, Qin B, et al. Targeting DNA methylation for treating triple-negative breast cancer[J]. Pharmacogenomics, 2019, 20(16): 1151–1157. doi: 10.2217/pgs-2019-0078
    [22]
    Shen MH, Jiang YZ, Wei Y, et al. Tinagl1 suppresses triple-negative breast cancer progression and metastasis by simultaneously inhibiting integrin/FAK and EGFR signaling[J]. Cancer Cell, 2019, 35(1): 64–80.e7. doi: 10.1016/j.ccell.2018.11.016
    [23]
    Liu JJ, Liu L, Yagüe E, et al. GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation[J]. Breast Cancer Res Treat, 2019, 174(1): 65–78. doi: 10.1007/s10549-018-5052-z
    [24]
    Qin JJ, Yan L, Zhang J, et al. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review[J]. J Exp Clin Cancer Res, 2019, 38(1): 195. doi: 10.1186/s13046-019-1206-z
    [25]
    Pollak M. Insulin and insulin-like growth factor signalling in neoplasia[J]. Nat Rev Cancer, 2008, 8(12): 915–928. doi: 10.1038/nrc2536
    [26]
    Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells[J]. Cancer Res, 2004, 64(11): 3892–3899. doi: 10.1158/0008-5472.CAN-03-2904
    [27]
    Lyons A, Coleman M, Riis S, et al. Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells[J]. J Biol Chem, 2017, 292(41): 16983–16998. doi: 10.1074/jbc.M117.792838
    [28]
    Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer?[J]. Am J Pathol, 2006, 169(5): 1505–1522. doi: 10.2353/ajpath.2006.051090
    [29]
    Parekh N, Guffanti G, Lin Y, et al. Insulin receptor variants and obesity-related cancers in the Framingham Heart Study[J]. Cancer Causes Control, 2015, 26(8): 1189–1195. doi: 10.1007/s10552-015-0613-5
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(3)

    Article Metrics

    Article views (156) PDF downloads(10) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return